These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 30462564)
1. Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus. Shi L; Zou Z; Ding Q; Liu Q; Zhou H; Hong X; Peng G Cancer Biol Ther; 2019; 20(4):431-434. PubMed ID: 30462564 [TBL] [Abstract][Full Text] [Related]
2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
3. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229 [TBL] [Abstract][Full Text] [Related]
4. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]
5. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146 [TBL] [Abstract][Full Text] [Related]
6. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410 [TBL] [Abstract][Full Text] [Related]
8. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692 [TBL] [Abstract][Full Text] [Related]
9. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972 [TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583 [TBL] [Abstract][Full Text] [Related]
11. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study. Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461 [TBL] [Abstract][Full Text] [Related]
12. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995 [TBL] [Abstract][Full Text] [Related]
13. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313 [TBL] [Abstract][Full Text] [Related]